1. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects and definition of disease severity;Martorell A;Actas Dermosifiliogr,2015
2. European S1 guideline for the treatment of hidradenitis supppurativa/acne inversa;Zoumboulis CC;J Eur Acad Dermatol Venereol,2015
3. World Health Organization.2009Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs).http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed February 19 2015.
4. European Medicines Agency.2017.Imraldi 40 mg solution for injection: summary of product characteristics.http://www.ema.europa.eu/. Accessed July 4 2018.
5. SB5: An Adalimumab Biosimilar